Company Overview and News

5
Cirtek nets $1.9M

2018-05-23 business.inquirer.net
Laguna-based electronics manufacturer Cirtek Holdings Philippines Corp. grew its first quarter net profit by 14 percent year-on-year to $1.9 million on higher sales coupled with improved margins.
PSKXF TECH PHSXY PSE

5
Cirtek nets $1.94 million in Q1

2018-05-22 bworldonline
CIRTEK Holdings Philippines Corp. (CHPC) grew its net income by 14% in the first quarter of 2018, driven by a double-digit increase in revenues following the consolidation of its recently acquired firm alongside higher sales from its semiconductor unit.
PSKXF TECH PHSXY PSE

0
Cirtek net income up by 14% on strong revenue growth

2018-05-21 bworldonline
Cirtek Holdings Philippines Corp. (CHPC) grew its net income by 14% in the first quarter of 2018, driven by a double-digit increase in revenues following the consolidation of its recently acquired firm alongside higher sales in its semiconductor unit.
TECH

16
Tech businesses powering Asia-Pacific growth

2018-04-05 bworldonline
London’s venerable Financial Times (FT) recently released its first-ever “FT 1000 High-Growth Companies Asia-Pacific” list — with 26 Filipino firms making the grade, all of which are listed on the Philippine Stock Exchange except for one.
JGSMY CNPF JGS ATI SGI CEBUY TUGS ACR SSI JBFCF MWP PHSXY H2O LNSTY PSE MWIDE CEB AISNY JGSHF CIC PSKXF JBFCY PRGLY PGOLD MBC PGCMF CROWN TECH STI CEBUF SPC JFC PERC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to PSE:TECH / Cirtek Holdings Philippines Corporation on message board site Silicon Investor.

Technology Stocks u0026 Market Talk With Don Wolanchuk The *NEW* Frank Coluccio Technology Forum
Technical Analysis for Macintosh Users StrikeForce Technologies
Biotech Valuation Verde Agritech
NanoViricides - Nanobiotechnology 2018 Biotech Charity Contest
SIGA Technologies Inc. biotech fireworks